BC Innovations | Apr 21, 2016
Distillery Therapeutics

Therapeutics: CC chemokine receptor 9 (CCR9; CDw199)

Gastrointestinal disease INDICATION: Colitis Cell line and mouse studies identified dioxoisoindoline-based CCR9 antagonists that could help treat colitis. Chemical synthesis of dioxoisoindoline analogs and testing in a human cell-based binding assay identified three compounds that...
BC Extra | Aug 23, 2013
Top Story

ChemoCentryx plummets on Phase III miss

ChemoCentryx Inc. (NASDAQ:CCXI) fell $3.37 (29%) to $8.32 on Friday after partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said vercirnon ( GSK1605786 ) missed the primary and secondary endpoints in the Phase III SHIELD-1 trial to treat Crohn's disease....
BC Week In Review | Jun 10, 2013
Clinical News

CCX507: Phase I data

A double-blind, placebo-controlled Phase I trial in healthy volunteers showed that 3, 10 and 30 mg doses of CCX507 were well tolerated with no serious events or withdrawals due to adverse events reported. Data were...
BC Week In Review | Jan 14, 2013
Clinical News

CCX507: Phase I started

ChemoCentryx began a double-blind, placebo-controlled Phase I trial to evaluate CCX507 in healthy volunteers. ChemoCentryx Inc. (NASDAQ:CCXI), Mountain View, Calif.   Product: CCX507   Business: Autoimmune   Molecular target: CC chemokine receptor 9 (CCR9) (CDw199)...
Items per page:
1 - 4 of 4